June 8, 2017August 24, 2022
Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows
News
Patients with unresectable or metastatic melanoma who were treated with Keytruda (pembrolizumab) in a pivotal clinical trial showed superior and sustained time ... Read more
June 6, 2017
New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test
News
Castle Biosciences presented three abstracts on the validity of using its 31-Gene Expression Profile (GEP) Test for melanoma prognosis at the ... Read more
June 1, 2017June 2, 2017
Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer
News
Biothera Pharmaceuticals will present the detailed study design of the IMPRIME-1 clinical trial at the upcoming 2017 ASCO Annual Meeting June 2-6 in ... Read more
May 30, 2017
Researchers Provide New Insights into Melanoma Immune Resistance
News
A new study presents detailed information into the processes used by cancer cells to evade and resist the immune response. Researchers studied ... Read more
May 25, 2017May 25, 2017
New Clinical Trial Underway for Treatment of Advanced Melanoma
News
A new clinical trial is underway assessing the addition of the first-in-class AXL kinase inhibitor, BGB324, to standard of care treatment for patients with ... Read more
May 23, 2017May 23, 2017
Skin Cancer Awareness Month Brings Sun Safety to Schools
News
Educating people of all ages, particularly children, about the dangers of sun exposure is urgent to preventing the increased prevalence ... Read more
May 18, 2017
First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma
News
The first patient has been enrolled in Targovax‘s pilot clinical trial for advanced or unresectable melanoma patients whose cancer progressed after treatment ... Read more
May 16, 2017
ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial
News
The combination of ImmunoPulse IL-12 and the anti-PD-1 therapy Keytruda (pembrolizumab) soon will be tested in a Phase 2 trial for treatment ... Read more
May 11, 2017
Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial
News
Adding the small molecule MEK inhibitor binimetinib to the BRAF inhibitor encorafenib was safe and significantly prolonged the time to disease progression ... Read more
May 9, 2017May 9, 2017
Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize
News
The Pershing Square Sohn Cancer Research Alliance has announced the six winners of the fourth edition of the annual Pershing ... Read more
May 4, 2017
Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma
News
Castle Biosciences’ DecisionDx-Melanoma test can be used to accurately predict cancer recurrence and metastasis in patients with head and neck melanoma, ... Read more
April 25, 2017
IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the ... Read more

October 6, 2014

Melanoma Incidence Linked to Socioeconomic Factors and Fashion Trends According to Study

News

A new study published in the American Journal of Public Health titled “More Skin, More Sun, More Tan, More Melanoma”, links cultural and historical forces to the increased incidence of ... Read more

October 3, 2014

Roche And GSK Melanoma Drug Combination Shows Similar Results

News

Results from recent clinical trials presented at the European Society of Medical Oncology annual congress in Madrid, showed that two of the new pill combinations for melanoma treatment from Roche ... Read more

October 2, 2014

Experimental Therapy Shows Promising Results in Melanoma

News

During the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, data from a clinical study assessing pembrolizumab for the treatment of melanoma showed promising activity and safety profiles. ... Read more

October 1, 2014October 1, 2014

Melanoma, Immunotherapy-Radiation Combination Therapy Continues To Show Promise

News

A new study addressing the effect of highly focused radiation in boosting the immune system to target and kill cancer cells upon combination with a novel type of immune-enhancing drug, was presented ... Read more

September 30, 2014September 30, 2014

Array’s Melanoma Drug Promising in Phase 2 Study

Melanoma, News

Array BioPharma Inc. recently presented the latest results of its Phase 2 clinical trial of binimetinib in patients with advanced NRAS mutant melanoma, at the European Society for Medical Oncology (ESMO) Annual Meeting ... Read more

September 29, 2014September 29, 2014

FDA Grants Priority Review to Nivolumab For Melanoma Treatment

Melanoma, News

PD-1 inhibitor nivolumab (Opdivo) has been granted a priority review designation by the American Food and Drug Association (FDA), as a treatment for pretreated patients with advanced melanoma. This decision ... Read more

September 26, 2014September 26, 2014

Deployed Military Have Higher Risk of Developing Skin Cancer

News

Soldiers who are deployed into locations with tropical and sunny climates are returning to the United States with a higher risk of developing skin cancer, as concluded by a retrospective ... Read more

September 25, 2014September 25, 2014

Results On New Melanoma Drug PV-10 To Be Presented At The European Society for Medical Oncology Congress

Melanoma, News

During this year’s European Society for Medical Oncology (ESMO) 2014 Congress, drug developer Provectus Biopharmaceuticals, Inc., will present a study entitled, “Subgroup efficacy in patients receiving intralesional rose bengal to all existing ... Read more

September 24, 2014September 24, 2014

Telomeres Length May Influence Risk of Developing Melanoma

Melanoma, News

People who have longer telomeres, a compound structure at the end of a chromosome, have higher risk of suffering from melanoma, according to the study “The effect on melanoma risk of ... Read more

September 23, 2014September 23, 2014

PD-L1 in Melanoma Identified As Negative Prognostic Marker

Melanoma, News

In a new study entitled “PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics”, published in the Annals of Oncology journal, a ... Read more

September 22, 2014September 22, 2014

Decision Resources Group Survey Shows that Half of Oncologists Prescribe Tafinlar and Mekinist to Treat Melanoma

Melanoma, News

The consulting company Decision Resources Group, which analyzes critical issues within the healthcare industry, recently concluded that more than half of the surveyed U.S. oncologists prescribe GlaxoSmithKline‘s BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or ... Read more

September 22, 2014September 22, 2014

Melanoma Risk Associated with Telomere Length, According to Study

Melanoma, News

Researchers from the University of Leeds, have published a new study entitled “The effect on melanoma risk of genes previously associated with telomere length,” published in the Journal of the National ... Read more

Keytruda Improves Survival in Advanced Melanoma Patients Compared to Yervoy, Phase 3 Trial Shows

New Evidence Presented on Accuracy of DecisionDx-Melanoma Prognosis Test

Biothera to Present Detailed Design of Combo Therapy Study for Melanoma, Breast Cancer

Researchers Provide New Insights into Melanoma Immune Resistance

New Clinical Trial Underway for Treatment of Advanced Melanoma

Skin Cancer Awareness Month Brings Sun Safety to Schools

First Patient Enrolled in ONCOS-102, Keytruda Combo Trial for Advanced Melanoma

ImmunoPulse IL-12 and Keytruda Combo Therapy to be Tested in Phase 2 Trial

Binimetinib Improves Progression-free Survival of Certain Melanoma Patients in Phase 3 Trial

Melanoma Scientist Among 6 in NYC Awarded Prestigious Research Prize

Castle’s Gene Test Shows Accuracy in Predicting Recurrence, Spread of Head and Neck Melanoma

IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group